このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

食事と運動で治療を受けた2型糖尿病患者において、カグリセマがプラセボと比較して血糖値と体重をどれだけ下げるかを調べる研究研究 (REIMAGINE 1)

2026年9月28日 更新者:Novo Nordisk A/S

カグリリンチドとセマグルチド(CagriSema)の皮下同時投与の有効性と安全性食事と運動の管理が不十分な2型糖尿病の参加者における週1回投与量2.4mg/2.4mgおよび1.0mg/1.0mgとプラセボの比較

This study will look at how much CagriSema helps participants with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participants will get either CagriSema or "dummy" medicine. Which treatment participants get is decided by chance. For each participant, the study will last for about one year.

調査の概要

研究の種類

介入

入学 (実際)

189

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Huntington Park、California、アメリカ、90255
        • Nat Res Inst Huntington Park
      • Northridge、California、アメリカ、91325
        • Valley Clinical Trials, Inc.
      • Santa Ana、California、アメリカ、92701
        • Southern California Dermatology
    • Florida
      • Hollywood、Florida、アメリカ、33024
        • Encore Medical Research LLC
      • Orlando、Florida、アメリカ、32819
        • Headlands Research Orlando
      • Weston、Florida、アメリカ、33331
        • Encore Medical Research of Weston
    • Kansas
      • Newton、Kansas、アメリカ、67114
        • Alliance for Multispec Res
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02115
        • Brigham & Women's Hospital
    • Michigan
      • Troy、Michigan、アメリカ、48098
        • Arcturus HC PLC Troy Med Res
    • New York
      • West Seneca、New York、アメリカ、14224
        • Southgate Medical Group, LLP
    • Oregon
      • Portland、Oregon、アメリカ、97210
        • Summit Research Network Oregon Inc.
    • Tennessee
      • Kingsport、Tennessee、アメリカ、37660
        • Holston Medical Group
    • Texas
      • Amarillo、Texas、アメリカ、79124
        • Amarillo Medical Specialists
      • Austin、Texas、アメリカ、78704
        • Elligo Clin Res Centre
      • Brownsville、Texas、アメリカ、78526
        • Headlands Research Brownsville
      • Dallas、Texas、アメリカ、75230
        • Velocity Clinical Res-Dallas
      • San Antonio、Texas、アメリカ、78233
        • Northeast Clinical Research of San Antonio
      • Shavano Park、Texas、アメリカ、78231
        • Consano Clinical Research, LLC
      • Sugar Land、Texas、アメリカ、77479
        • Sugar Lakes Family Practice PA
      • Weslaco、Texas、アメリカ、78596
        • Valley Diab. & Endo Comp Ctr
    • Virginia
      • Newport News、Virginia、アメリカ、23606
        • TPMG Clinical Research
      • Bergamo、イタリア、24127
        • Azienda Ospedaliera Papa Giovanni XXIII
      • Catanzaro、イタリア、88100
        • Policlinico Mater Domini Università di Catanzaro
      • Milan、イタリア、20132
        • IRCCS Ospedale San Raffaele Milano
      • Roma、イタリア、00161
        • Azienda Ospealiero Universitaria Policlinico Umberto I
      • Al Ahsa、サウジアラビア、36428
        • King Abdulaziz Hospital-Al Ahsa-National Guard
      • Jeddah、サウジアラビア、21423
        • National Guard Hospital - Jeddah
      • Riyadh、サウジアラビア、11525
        • King Fahad Medical City
      • Riyadh、サウジアラビア、12372
        • King Khaled University Hospital,King Saud Univ. Med. City
      • Riyadh、サウジアラビア、12769
        • King Salman Bin Abdulaziz Hospital
      • Belgrade、セルビア、11080
        • Clinical Hospital Center Bezanijska Kosa
      • Belgrade、セルビア、11080
        • Clinical Hospital Centre Zemun
      • Belgrade、セルビア、11000
        • CHC Zvezdara, Clinical department for endocrinology
      • Zaječar、セルビア、19000
        • Policlinic for diabetes
      • Budapest、ハンガリー、1032
        • Szent Margit Rendelőintézet Nonprofit Kft.
      • Budapest、ハンガリー、1102
        • PVN Kutató Kft.
    • Hajdú-Bihar
      • Debrecen、Hajdú-Bihar、ハンガリー、4025
        • Belinus Bt.
    • Szabolcs-Szatmar Varmegye
      • Nyíregyháza、Szabolcs-Szatmar Varmegye、ハンガリー、4405
        • Borbánya Praxis E.Ü. Kft.
      • Bialystok、ポーランド、15-351
        • Osteo-Medic s.c. A. Racewicz, J. Supronik
      • Bialystok、ポーランド、15-797
        • Renew Clinic Sp. z o.o.
      • Lodz、ポーランド、90-338
        • Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
      • Warsaw、ポーランド、02-507
        • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I Administracji
      • Warsaw、ポーランド、00-710
        • NBR Polska Tomasz Klodawski
      • Zamość、ポーランド、22-400
        • Velocity Nova Sp. z o.o.
    • Podkarpackie Voivodeship
      • Rzeszów、Podkarpackie Voivodeship、ポーランド、35-055
        • Centrum Medyczne Medyk Sp. z o.o.
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100853
        • Chinese People's Liberation Army General Hospital-Endocrinology
    • Jiangsu
      • Nanjing、Jiangsu、中国、210011
        • The Second Affiliated Hospital of Nanjing Medical University-Endocrinology
      • Zhenjiang、Jiangsu、中国、212001
        • The Affiliated Hospital of Jiangsu University-Endocrinology
    • Shandong
      • Ji'Nan、Shandong、中国、250000
        • Jinan Central Hospital
      • Jinan、Shandong、中国、250000
        • Jinan Central Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Male or female
  • Age 18 years or above at the time of signing the informed consent
  • Diagnosed with type 2 diabetes >=30 days before screening
  • HbA1c 7.0-9.5 percent (53-80 millimoles per mole [mmol/mol]) (both inclusive) as determined by central laboratory at screening
  • Body mass index (BMI) >=23 kilograms per square meter (kg/m^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method
  • Renal impairment with estimated Glomerular Filtration Rate less than 30 milliliter per minute per 1.73 square meter (ml/min/1.73 m^2) as determined by central laboratory at screening
  • Treatment with any medication for the indication of diabetes or obesity within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
  • History of use of any injectable therapy for diabetes or obesity. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:CagriSema Dose 2

Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 16-week dose escalation period until target dose (dose 2) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 24 weeks.

Participants will receive once-weekly cagrilintide subcutaneously.

Participants will receive once-weekly semaglutide subcutaneously.

プラセボコンパレーター:Placebo Dose 2

Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 2 for 40 weeks.

Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

アクティブコンパレータ:Cagrisema Dose 1

Participants will receive once-weekly subcutaneous (s.c) injections of CagriSema (cagrilintide and semaglutide) at escalating doses every week in 8-week dose escalation period until target dose (dose 1) of CagriSema (cagrilintide and semaglutide) is achieved and maintained up to 32 weeks.

Participants will receive once-weekly cagrilintide subcutaneously.

Participants will receive once-weekly semaglutide subcutaneously.

プラセボコンパレーター:Placebo Dose 1

Participants will receive once-weekly s.c injection of placebo matched to Cagrisema (cagrilintide and semaglutide) dose 1 for 40 weeks.

Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in glycated haemoglobin (HbA1c)
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as percentage (%)-points.

From baseline (week 0) to end of treatment (week 40)

二次結果の測定

結果測定
メジャーの説明
時間枠
Relative change in body weight
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured in %.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve greater than or equal to (>=) 10% body weight reduction
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve >=15% body weight reduction
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve HbA1c target values of less than (<) 7.0% (<53 millimoles per mole [mmol/mol])
時間枠:At end of treatment (week 40)

Measured as count of participants.

At end of treatment (week 40)
Number of participants who achieve HbA1c target values of less than or equal to (<=) 6.5% (<= 48 mmol/mol)
時間枠:At end of treatment (week 40)

Measured as count of participants.

At end of treatment (week 40)
Change in Fasting Plasma Glucose (FPG)
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured in millimoles per liter (mmol/L).

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve >=5% body weight reduction
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve >=20% body weight reduction
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as count of participants.

From baseline (week 0) to end of treatment (week 40)
Change in waist circumference
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured in centimeters (cm).

From baseline (week 0) to end of treatment (week 40)
Change in systolic blood pressure (SBP)
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured in millimeters of mercury (mmHg).

From baseline (week 0) to end of treatment (week 40)
Change in diastolic blood pressure (DBP)
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured in mmHg.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in high sensitivity C-reactive protein (hsCRP)
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Total cholesterol
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: High-density lipoprotein (HDL) cholesterol
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Low-density lipoprotein (LDL) cholesterol
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Very low-density lipoprotein (VLDL) cholesterol
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Triglycerides
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Free fatty acids
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Ratio to baseline in lipids: Non-HDL cholesterol
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Number of participants who achieve type 2 diabetes (T2D) remission (HbA1c <6.5% and no antidiabetic medication)
時間枠:At end of study (week 52)

Measured as count of participants.

At end of study (week 52)
Ratio to baseline in oral glucose tolerance test (OGTT) based oral glucose disposition index (DIo)
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as ratio.

From baseline (week 0) to end of treatment (week 40)
Change in experienced level of energy as measured by the SF-36v2 Health Survey Acute (SF-36v2) Vitality score
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as score points. SF-36v2 Acute measures Health-Related Quality of Life (HRQoL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10.

Higher scores indicate better functional health and well-being. The vitality score range is from 25.6 to 69.1.

From baseline (week 0) to end of treatment (week 40)
Change in SF-36v2 score: Physical Component Summary score
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for physical component summary is 6.1 to 79.7.

From baseline (week 0) to end of treatment (week 40)
Change in SF-36v2 score: Mental Component Summary score
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as score points. SF-36v2 Acute measures HRQoL. The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 Acute scores are norm-based scores, that is. transformed to a scale where the 2009 US general population has a mean of 50 and a standard deviation of 10. Higher scores indicate better functional health and well-being. The score range for mental component summary score is -3.8 to 78.7.

From baseline (week 0) to end of treatment (week 40)
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured as score points. DTSQs measures treatment satisfaction and diabetes-specific quality of life. The measure consists of 8 items yielding 1 global score and 2 single item scores. Higher scores on the global score indicate greater satisfaction with treatment. Lower scores on the single-item scores indicate BG levels closer to the ideal, while higher scores indicate problems. Single-item scores (score range): Perceived frequency of hyperglycaemia (0-6), Perceived frequency of hypoglycaemia (0-6). Global score (score range): Total Treatment Satisfaction (0-36).

From baseline (week 0) to end of treatment (week 40)
Change in leptin
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured in nanograms per milliliter (ng/mL).

From baseline (week 0) to end of treatment (week 40)
Change in soluble leptin receptor
時間枠:From baseline (week 0) to end of treatment (week 40)

Measured in ng/mL.

From baseline (week 0) to end of treatment (week 40)
Number of Treatment Emergent Adverse Events (TEAEs)
時間枠:From baseline (week 0) to end of treatment +7 weeks (week 47)

Measured as count of events.

From baseline (week 0) to end of treatment +7 weeks (week 47)
Number of clinically significant hypoglycaemic episodes (level 2) (<3.0 mmol (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose (BG) meter
時間枠:From baseline (week 0) to end of treatment +7 weeks (week 47)

Measured as count of episodes.

From baseline (week 0) to end of treatment +7 weeks (week 47)
Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold
時間枠:From baseline (week 0) to end of treatment + 7 weeks (week 47)

Measured as count of episodes.

From baseline (week 0) to end of treatment + 7 weeks (week 47)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Clinical Transparency (dept. 2834)、Novo Nordisk A/S

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年3月19日

一次修了 (実際)

2025年10月1日

研究の完了 (実際)

2025年12月22日

試験登録日

最初に提出

2024年3月15日

QC基準を満たした最初の提出物

2024年3月15日

最初の投稿 (実際)

2024年3月21日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月30日

QC基準を満たした最後の更新が送信されました

2026年9月28日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • NN9388-4895
  • 2022-502677-42 (その他の識別子:European Medical Agency (EMA))
  • U1111-1283-0404 (その他の識別子:World Health Organization (WHO))

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する